Terns Pharmaceuticals Inc

CEO Amy Burroughs buys Terns Pharmaceuticals shares at $4.64 after selling high‑price blocks, showing disciplined Rule 10b5‑1 confidence and a potential near‑term upside for investors.

Insider confidence fuels hope for Terns Pharmaceuticals as six directors exercise $0 stock options, hinting at future breakthroughs and a potential price rebound.

Insider buying surge at Terns Pharmaceuticals: CMO, CFO, CEO lock in 356k shares and options, hinting at a bullish pipeline amid high volatility.